1995
DOI: 10.1002/art.1780380620
|View full text |Cite
|
Sign up to set email alerts
|

Comparative prospective, double‐blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of paget's disease of bone

Abstract: Objective. To compare the efficacy and safety of tiludronate and etidronate at the same dosage (400 mg/day) for the treatment of active Paget's disease of bone.Methods. We studied 234 patients with radiologic lesions characteristic of Paget's disease of bone and serum alkaline phosphatase (AP) concentrations at least twice the upper limit of normal, in a prospective, randomized, double-blind, multicenter clinical trial lasting 6 months. Patients were randomly allocated into 1 of 3 treatment groups: tiludronate… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
28
0
4

Year Published

1999
1999
2017
2017

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 109 publications
(35 citation statements)
references
References 25 publications
(20 reference statements)
3
28
0
4
Order By: Relevance
“…Similar results were previously reported for patients resistant to etidronate who were shown to respond to other BPs. (16,17) …”
Section: Resistance To Treatment With Other N-bpsmentioning
confidence: 99%
“…Similar results were previously reported for patients resistant to etidronate who were shown to respond to other BPs. (16,17) …”
Section: Resistance To Treatment With Other N-bpsmentioning
confidence: 99%
“…No detrimental effect of this compound on the biomechanical resistance of trabecular and cortical bone was observed [15]. In patients with Paget's disease of bone, the daily administration of tiludronate 400 mg/day for 3-6 months was shown to be more effective than the same dose of etidronate for 6 months [17]. Tiludronate, given daily for 6 months to healthy early postmenopausal women, prevented spinal bone loss for up to 12 months, compared with women who received the placebo for the same duration [19].…”
Section: Discussionmentioning
confidence: 97%
“…In animal models involving rodents [14] and primates [15], tiludronate administration was demonstrated to decrease bone resorption, increase bone mineral density and preserve biochemical properties of the bones. Tiludronate was investigated in Paget's disease of bone, where dramatic and prolonged reductions of biochemical markers of bone remodeling were reported after oral intake, without the occurrence of clinically relevant adverse reactions [16][17][18]. When given to early postmenopausal women, tiludronate prevented spinal [19] and femoral [20] bone loss with a safety profile similar to the one observed in the placebo group [12].…”
Section: Introductionmentioning
confidence: 99%
“…Todos los bifosfonatos con indicación han demostrado reducción del dolor en la EP (tabla 1) aunque no se han encontrado diferencias significativas entre ellos (22)(23)(24)(25).…”
Section: Eficacia En El Control De Las Manifestaciones Clínicasunclassified